Our institution's experience with low anterior resection in combination with coloanal anastomosis (LAR/CAA) for primary rectal cancer was reviewed (1) to determine cancer treatment results, 2) to identify risk factors for pelvic recurrence, and 3) to assess the long-term success of sphincter preservation.
Summary Background Data
Use of sphincter-preserving resection for mid-rectal and selected distal-rectal cancers continues to increase. As surgical techniques and adjuvant therapy evolve, treatment results must be carefully assessed.
Methods
One hundred thirty-four patients treated for primary rectal cancer by LAR/CAA between 1977 and 1990 were studied retrospectively. All pathologic slides were reviewed. Median follow-up was 4 years.
Results
Actuarial 5-year survival for all patients was 73%. Among 36 patients who relapsed, distant metastatic disease had developed at the time of first clinical relapse in most (86%). Pelvic recurrence was detected in 13 patients, an actuarial rate of 1 1 % at 5 years. Mesenteric implants, positive microscopic resection margin, T3 tumor, perineural invasion, blood vessel invasion, and high tumor grade were associated with increased risk for pelvic recurrence. Eleven patients ultimately required permanent colostomy, and in eight instances the cause was pelvic recurrence.
Conclusions
Low anterior resection combined with coloanal anastomosis provides good treatment for midrectal cancers and for some distal rectal cancers. Pelvic recurrence is not associated with short distal resection margins but is correlated with the presence of histopathologic markers of aggressive disease in the primary tumor. Long-term preservation of anal sphincter function depends primarily on control of pelvic tumor and can be achieved in more than 90% of patients.
When the distal margin of low anterior resection (LAR) reaches the anal canal, an intrapelvic anastomosis is no longer possible, and restoration of intestinal continuity requires coloanal anastomosis (CAA). Since its introduction 20 years ago by Sir Alan Parks,' oncologic treatment results of LAR/CAA for rectal cancer have been reported in only a few series, with pelvic recurrence rates of 5% to 20%. 2- With the advent of circular stapling devices, many mid-rectal cancers that previously required LAR/CAA are now treated using conventional LAR with a stapled anastomosis in the distal pelvis.8 9 Therefore in the past decade, case selection for LAR/CAA has evolved toward more distal rectal tumors that lie just above the anal canal. Increasing acceptance of short distal margins'0 and increasing confidence in the benefit of adjuvant pelvic radiation6"' also have contributed to the increased use of LAR/CAA for low-lying tumors in which distal and lateral clearance may be minimal.
Coloanal anastomosis in combination with low anterior resection has been used to treat rectal cancer at Memorial Sloan-Kettering Cancer Center since 1977. Our early experience, first reported in 1985, focused on patients with mid-rectal cancers in whom LAR was accomplished but colorectal anastomosis was technically impossible.4 In this report we update our experience with this procedure, assess risk factors for pelvic recurrence, and evaluate its role and adequacy as a cancer operation.
PATIENTS AND METHODS Patients
Patients were identified by reviewing hospital charts, office records, operating room records, and a prospective clinical database established by the Colorectal Service in 1986. Criteria for LAR/CAA included complete proctectomy and restorative anastomosis to the anal canal. The superior margin, or apex, of the anal canal is defined by the anorectal ring, the sling of muscle forming the anal hiatus of the pelvic diaphragm (Fig. 1) . In all cases the anastomosis was created at or below the apex ofthe anal canal. Conformity to these criteria was determined in each case by review of the operative note, the database entry by the operating surgeon, and the first postoperative digital/proctoscopic examination. tients had LAR/CAA at our institution. Seven patients were resected for villous adenoma and one for recurrent rectal cancer. The remaining 134 patients who had LAR/ CAA for primary, invasive rectal cancer form the basis of this report. We included 90 men (67%) and 34 women (33%). The median age was 59 years (range, 23 to 90 years). The height of the primary tumor was determined before operation by the attending surgeon on rigid proctoscopy in the left lateral Sims' position. The distance from the anal verge to the lowest edge of the tumor ranged from 2 cm to 11 cm, with a median distance of6.5 cm (Fig. 2) . Most tumors were clustered near the junction ofthe lower rectum (0 to 5 cm) and the mid-rectum (6 to 11 cm). The median tumor diameter was 4 cm (range, 1.5 to 8 cm). Most tumors were mobile; three fixed tumors were treated first with preoperative combined chemotherapy and radiation and then were resected with negative margins. Five patients had been treated by an initial transanal local excision and then resection because of positive pathologic findings and suspicion ofresidual disease.
Surgical Technique
Each patient was placed in the lithotomy position and explored through a midline abdominal incision. The rectum and its mesentery were sharply dissected to the anal hiatus of the pelvic diaphragm. The plane of pelvic dissection was generally the parietal pelvic (endopelvic) fascia with preservation ofthe sacral parasympathetic nerve roots and hypogastric nerve trunks; that is, nerve-preserving pelvic sidewall dissection. ' 
Pathologic Findings
All specimens were examined fresh by a pathologist for gross assessment, measurements of tumor size, and inking of margins. Distal resection margin was measured in the unpinned fresh specimen from the lowest edge of the visible tumor to the distal end of the specimen. Tumor extended grossly to the transected edge of the specimen in no cases. In 128 cases, a distal resection margin was measured and recorded (range, 0.5 cm to 8 cm; median, 2 cm). In 6 cases, distal resection margin could not be assigned because the pathologist did not record the measurement (2 cases), because of re-excisions ofthe distal rectal stump (1 case), or because of complete tumor regression after preoperative pelvic radiation therapy (3 cases).
After fixation in 10% formaldehyde, sections were taken routinely from the primary tumor, adjacent rectum. and from the proximal, distal, and lateral margins. All lymph nodes retrieved either by visual examination or by palpation were submitted for microscopic examination. All histologic slides were reviewed by one pathologist (G.L.). For the eight cases in which slides were not available, the original pathology reports were accepted.
Three patients had no residual tumor after preoperative radiation therapy and were not assigned a tumor stage. (Fig. 3) 
Adjuvant Therapy
Adjuvant pelvic radiation was given to 65 patients in a variety of doses and schedules (Table 1) . Most patients receiving preoperative radiation therapy were enrolled in one of three clinical trials conducted at our institution during the period ofstudy: (1) 15 Gy administered before operation for resectable rectal cancer as part of a sandwich strategy (27 patients)'6; (2) 50 Gy administered before operation followed by LAR/CAA as an alternative to abdominoperineal resection in selected patients with low rectal cancers 3 to 6 cm above the anal verge (23 patients)"; (3) 50 Gy with 5FU/leucovorin administered before operation for locally advanced rectal cancer (3 patients).'7 Ten patients received postoperative radiation therapy because of regional lymph node involvement. Sixty-nine patients received no radiation therapy. Nineteen patients received postoperative adjuvant chemotherapy.
Assessment
Four clinical end points were assessed: (1) pelvic recurrence, (2) distant recurrence, (3) need for permanent colostomy, (4) 
RESULTS Survival
There were no hospital deaths. Twenty-nine patients have died of rectal cancer, 4 with persistent liver metastases and 25 with recurrence. Three patients are alive with disease. The actuarial probability of surviving cancer for 5 years is 73% (Fig. 4) 
Patterns of Recurrence
Thirty-six patients had relapse after potentially curative resection. The sites oftumor recurrence are listed in (Fig. 5) . Median time to pelvic recurrence for the 13 patients was 18 months (range, 3 to 51 months).
A suture line recurrence in the anal canal developed in 1 one patient and was cured by abdominoperineal resection. Of the 12 patients in whom true intrapelvic recurrence developed, 7 had special risk factors for recurrence (Table 3) : microscopic involvement of a resection margin (2 patients) and mesenteric tumor implants (6 patients). In the absence of these special findings, there were Of the 12 patients with intrapelvic recurrence, 9 are dead of their disease, 2 are alive with disease, and 1 has no evidence of disease 18 months after salvage abdominoperineal resection.
Prognostic Factors for Pelvic Recurrence
To understand the causes of local failure, we performed a univariate analysis of possible risk factors. We examined patient factors, tumor factors, and treatment factors for statistical correlation with the development of pelvic recurrence (Table 4) .
Of the patient and tumor factors, mesenteric tumor implants, perineural invasion, blood vessel invasion, transmural penetration of tumor (T3), and poorly differentiated histology were significantly associated with pelvic recurrence. Lymphatic vessel invasion also correlated with recurrence but fell just short of statistical significance (p = 0.06). Age, sex, tumor height above the anal verge, tumor size, and lymph node metastases had no demonstrable effect on pelvic recurrence.
Ofthe treatment factors, only positive microscopic involvement of a resection margin was predictive of pelvic recurrence. In two cases margins initially thought to be negative at surgery were found to be positive on final histopathologic examination, and pelvic recurrence developed in both patients (Table 3 ). In one patient a compromised distal margin occurred despite a 3-cm gross resection margin below the tumor. Permanent histologic sections of the distal margin revealed unsuspected adenocarcinoma arising within an adenomatous polyp at the edge of the resected specimen. In a second patient, compromised lateral margins occurred with extensive multifocal involvement ofthe mesorectum by tumor implants, one of which extended to the lateral pelvic margin. In both cases, positive resection margins were attributed to locally advanced tumors with unsuspected, discontiguous foci of disease rather than grossly unsafe resection margins selected by the surgeon.
The length of the distal resection margin below the tumor (< 2 cm compared with .2 cm) had no statistical relation to pelvic recurrence (Table 4 ). In patients resected with short distal margins, the crude rate of local control was 94% (45 of 48 cases) compared with a crude rate of 89% (71 of 80 cases) in those with longer margins. The favorable outcome with short distal margins is unlikely to be related to a selection bias because patients with short and long distal margins had similar distributions of tumor stage and received adjuvant pelvic radiation in similar schedules and frequencies (Table 5 ). Neither adjuvant chemotherapy nor adjuvant radiation therapy had any correlation with pelvic recurrence in this series (Table 4) .
Permanent Colostomy
One hundred twenty-three patients maintained intestinal continuity during follow-up. Eleven patients needed permanent colostomy (Table 6 ). Eight of these colostomies were performed for pelvic recurrence. One patient declined reversal of his loop colostomy. One severe anastomotic stricture and one intractable rectourethral fistula, both occurring in patients treated with post- 
DISCUSSION
The primary goal of operations for rectal cancer is complete resection of all regional disease to achieve the best chance for local control and cure. Operative technique effects rates ofpelvic recurrence, which range from roportion free of pelvic recurrence under 10% to nearly 40%.19,20 Sharp dissection along the pelvic sidewalls and complete excision of the mesorectum are important means to achieve complete resec- 21, 22 tion.
The decision to proceed with LAR/CAA is made in the operating room and is based on two judgments by the surgeon: (1) that the rectal tumor can be adequately resected without violating the levator ani and anal sphincter muscles, and (2) that intrapelvic anastomosis is technically impossible. This circumstance occurs most often with tumors located at or near the junction of the lower third and middle third ofthe rectum; that is, about 6 cm above the anal verge. Two thirds of our patients were men; this reflects the added difficulty of constructing a low anastomosis beneath the prostate gland in a narrow male pelvis. Pathologic distal margins were relatively short (range, 0.5 to 8 cm; median, 2 cm). Together these data confirm that LAR/CAA was used on a highly selective basis for tumors lying near the pelvic floor but not grossly invading either the levator ani or the anal canal.
The overall treatment results were good: 73% survival and 89% local control rates at 5 years. Approximately two thirds of all relapses were at distant sites alone. Risk factors for pelvic recurrence (Table 4) were primarily pathologic indicators of locally advanced or aggressive disease that relate to the degree and pattern of tumor spread into perirectal tissues: tumor implants in the Table 4 ). These figures suggest that for this operation, as shown for conventional LAR,'025 longer distal margins do not improve cancer treatment. In experienced hands, compromise of resection margins is rare; gross findings in the operating room will guide the surgeon appropriately.
Long-term sphincter preservation was achieved in 92% ofpatients; most colostomies were required because of pelvic recurrence. These data underscore that the first priority ofsphincter preservation must be successful cancer treatment.
Adjuvant pelvic radiation reduces local recurrence of rectal cancer after conventional resection and is usually recommended in combination with 5-fluorouracilbased chemotherapy after resection of transmural tumors (T3-4) and node-positive (N1-2-3) tumors.26 '27 Our data indicate that, in the absence of other adverse Our experience indicates that postoperative radiation, when used in combination with LAR/CAA, has significant risks and deleterious effects. Of 10 patients receiving full-dose, postoperative pelvic radiation after LAR/ CAA, 2 required permanent colostomy for radiation-related complications (Table 5 ). In addition, a detailed survey of long-term anorectal function in the patients who maintain intestinal continuity showed impaired function in the group receiving postoperative radiation.29 Considering the relatively low pelvic recurrence rate observed in T3NO lesions and N1-2 lesions and the high incidence of additional histopathologic risk factors in those tumors that did recur in the pelvis, routine use of postoperative pelvic irradiation for all T3 or N 1 tumors may be excessive. A more selective use based on the extent of transmural penetration, the number of lymph nodes involved, and the presence or absence of additional histopathologic risk factors identified here should be possible. In cases of early transmural spread or involvement of a single pericolonic lymph node and with no additional adverse factors, we recommend a careful discussion with the patient ofthe potential risks and benefits ofadjuvant therapy before referral for postoperative chemotherapy and radiation.
Preoperative pelvic radiation followed by LAR/CAA, on the other hand, was well tolerated in our patients. As better preoperative selection criteria for high-risk tumors become available, this sequence of therapy should be used more widely.
We used preoperative radiation in combination with LAR/CAA primarily for low-lying rectal cancers (3 to 6 cm above the anal verge) that might otherwise require abdominoperineal resection.7 In 22 patients treated by this approach between 1986 and 1992, 5 had local recurrence, with median follow-up of 29 months (4-year actuarial rate of pelvic recurrence is 32%).12 Attempts to extend sphincter preservation to this subset of low rectal cancers remain investigational; our protocol used preoperative radiation in combination with 5-fluorouracil and leucovorin. '9 Our experience also supports the use of LAR/CAA in patients with liver metastases if liver involvement is not massive. Ten such patients in our series have survived for a median of 32 months (range, 9 to 53 months). All had their diverting colostomies closed, and quality oflife was enhanced for most. However, there is a well-recognized and often stressful 6-to 12-month period of functional adaptation after colostomy closure. Patients who are not expected to survive much beyond this period may be better served by local excision.
Current guidelines for LAR/CAA provide good treatment for rectal cancer without compromising local control or survival. Careful attention to patient selection and operative technique is important to obtain good results. A pelvic recurrence rate of 11% has been observed, and most recurrences are associated with extraordinary risk factors. Current evidence suggests that preoperative pelvic radiation is significantly better tolerated than postoperative radiation. Overall more than 90% of patients avoid permanent colostomy.
